BRAK/CXCL14 is a chemokine that is expressed in many normal cells and tissues but is absent from or expressed at very low levels in transformed cells and cancerous tissues including head and neck squamous cell carcinoma (HNSCC). We reported previously that the forced expression of BRAK/CXCL14 in HNSCC cells decreased the rate of tumor formation and size of tumor xenografts in athymic nude mice and SCID mice, suggesting that expression level of the gene is important for tumor suppression. In order to study the regulatory mechanisms governing the expression of this gene, we determined the transcriptional start site and promoter motifs of the gene. The major transcriptional start site determined by 5' rapid amplification of cDNA end method was located 283 bp downstream of the first proposed site of the gene. Determination of luciferase activities of reporter gene constructs with various deletions or mutations showed that an atypical TATA-like sequence, TATTAA was essential for the transcription of the gene and that the AP-1 binding sequence and tandem GC box were necessary for stimulating the expression of the gene in human squamous epithelial cells. The human DNA region was highly homologous (95% base identity) to the mouse gene. In addition, okadaic acid, an inhibitor of serine/threonine phosphatases 1, 2A and 2B, stimulated TATTAA sequence and AP-1 binding-sequence dependent promoter activity as well as increased the level of BRAK/CXCL14 mRNA, indicating that these sequences are essential for the regulation of BRAK/CXCL14 gene expression in the cells.
was reported to induce B cell, monocyte (27) , and dendritic cell infiltration into normal and tumour tissues (26) and to inhibit angiogenesis (25) . Generally, BRAK/CXCL14 is expressed universally and abundantly in normal tissues (16) but is absent from or expressed only in a very small amount in cancerous tissues in vivo and in carcinoma cells in culture, including head and neck squamous cell carcinoma (HNSCC) cells (9, 12, 15, 25) . On the other hand, heightened BRAK/CXCL14 expression has been reported to occur in adenocarcinomas such as prostate (24) , breast cancers (2) and in pancreatic cancer cells (30) . These data suggest that effects of BRAK/ CXCL14 on the development and progression of cancer may be quite different between HNSCC and adenocarcinoma. In prostate cancer, BRAK/CXCL14 obtained from Sigma (Tokyo, Japan), and gentamicin sulfate and Trypsin 250 were from Wako Pure Chemical Industries (Osaka, Japan). DNA blunting kit and Mg 2+ /Ca 2+ -free phosphate-buffered saline tablets [PBS(−)] were purchased from TAKARA BIO (Shiga, Japan); and Fungizone and TRIzol ® from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) came from Thermo Electron (Melbourne, Australia); and FuGENE 6 transfection reagent from Roche Diagnostics K.K. (Tokyo, Japan). Okadaic acid sodium salt was purchased from CAL-BIOCHEM (Darmstadt, Germany).
Cells and cell culture. HNSCC cell lines used (HSC-2 derived from the oral floor, HSC-3 and HSC-4 derived from the tongue, and KB from a pharyngeal carcinoma) were obtained from the Japanese Collection of Research Bioresources (JCRB). The cells were cultured in Dulbecco's modified Eagle's medium containing gentamicin sulfate (50 mg/L) and Fungizone (250 μg/L). The medium was also supplemented with 10% FBS. The cells were cultured at 37°C under 95% air and 5% CO 2 and routinely passaged by treatment with 0.25% trypsin/1 mM ethylenediaminetetraacetic acid in PBS(−). Human fetal skin keratinocytes and serum-free Keratinocyte Growth Medium were obtained from Cell Applications Inc. (CA, USA).
Reverse transcriptase-polymerase chain reaction (RT-PCR) and gel electrophoresis.
RT-PCR for determination of BRAK/CXCL14 and β-actin mRNAs and identification of PCR products were performed as described earlier (20) .
Determination of 5' end of the gene by 5' Rapid Amplification of cDNA End (5'-RACE) method.
Total RNA was extracted with TRIzol ® reagent from cells; and after the RT reaction, the 5' terminal region of the cDNA was determined by 5'-RACE method by use of a 5'-Full RACE Core Set (TAKARA BIO). After cloning the 5'-RACE product into a pGEM-T easy vector (Promega, Tokyo, Japan) by the TA cloning strategy, we determined the transcriptional start site by sequencing with a CEQ2000 DNA analysis system and Genome Lab™ DTCS-Quick Start Kit (BECKMAN COULTER, CA, USA).
Construction of luciferase reporter gene vectors.
Genomic DNA was obtained from KB cells and the BRAK/CXCL14 gene and its upstream sequences were amplified by PCR methods using Fusion™ DNA Polymerase (FINNZYMES, Espoo, Finland). mRNA is significantly up-regulated in localized prostate cancer and its level positively correlates with the Gleason score. But interesting enough overexpression of normal BRAK/CXCL14 in prostate cancer cells by introducing mouse or human BRAK/ CXCL14 expression vectors retards tumor growth in vivo compared with the growth of control vectortransfected tumor cells (24) . These data suggest another possibility that expression of non-functional BRAK/CXCL14 molecules might be associated with stimulation of tumor growth in several adenocarcinoma cells, whereas normal functioning BRAK/ CXCL14 molecules might suppress tumor growth in vivo in adenocarcinoma as well as in HNSCC. Recently importance of BRAK/CXCL14 produced by cancer cell-associated fibroblasts was reported (3) . These data indicate further investigation is needed to clarify this apparent discrepancy of the effect of BRAK/CXCL14 on cancer progression of HNSCC and adenocarcinoma. We reported previously that the forced expression of BRAK/CXCL14 in HN-SCC cells decreased the rate of tumor formation and size of tumor xenografts in athymic nude mice (20) and SCID mice (21) . Interestingly, the oral administration of gefitinib, an epidermal growth factor tyrosine kinase inhibitor, significantly (P < 0.001) reduced tumor growth of xenografts of 3 HNSCC cell lines (HSC-2, HSC-3 and HSC-4) in female athymic nude mice, which reduction was accompanied by an increase in BRAK/CXCL14 expression specifically in the tumor tissue. This tumor-suppressing effect of the drug was not observed in the case of BRAK/CXCL14 non-expressing cells. Furthermore, the introduction of a vector expressing short hairpin RNA against BRAK/CXCL14 reduced both the expression levels of BRAK/CXCL14 in HSC-3 cells and the antitumor efficacy of gefitinib in vivo (19) . These results indicated that regulation of the gene expression might be very important to understand the function of this chemokine in tumor progression and suppression as well as in other physiological and pathological processes. In order to define the regulatory mechanisms governing the expression of this gene, we first investigated the transcriptional start site and proximal promoter elements of the gene and thereby identified a major transcriptional start site and characterized the proximal promoter elements of the gene in human squamous epithelial cells.
MATERIALS AND METHODS
Materials. Dulbecco's modified Eagle's medium was restriction enzymes and ligated, except for the pGL −557/+193 insert. In this case the vector was blunt ended with a DNA blunting kit and ligated. All the vectors were purified by use of a Pure Link Hipure Plasmid Maxiprep Kit (Invitrogen) and the sequence fidelity of all inserts was verified by sequencing as described above.
Transient transfection and luciferase assays. Logphase cells were trypsinized and plated onto well bottoms of 96-well ViewPlate ® -96TC (PerkinElmer, Massachusetts, USA). The cells were transfected 1 day after having been seeded at a density of 5000 cells per well. For the transfection, 1 μg of individual reporter gene construct and 30 ng of sea pansy luciferase vector were mixed with 3 μL of the transfection reagent (FuGENE 6) as described previously (1) . Luciferase activities were determined by using the Dual-Glo™ Luciferase Assay System (Promega). Samples were collected 1 day after 1 or 2 days of transfection period and luminescence was measured with a CT-9000D luminometer (Mitsubishi Kagaku Iatron, Inc). Values of firefly luciferase activity were normalized by those of Renilla luciferase (pGL4.73) activity in individual experiments.
Statistical analysis. In the determinations of luciferase activities, the values from 8 separately transfected wells for each construct were obtained and expressed as the mean ± SD. Relative luciferase activities in each experiment were expressed as a percentage of the highest activities. Student's t-test was used to assess statistically significant differences between 2 groups, with P < 0.05 being considered statistically significant.
RESULTS AND DISCUSSION

Determination of transcriptional start site by 5'-RACE method
In order to determine the transcriptional start site, we applied the 5'-RACE method to cDNAs prepared from mRNAs obtained from cell lines HSC-2, HSC-3, HSC-4, and normal human fetal skin keratinocytes. The results revealed that the major and most upstream transcription start site was located at +284 of previously proposed exon 1 in HSC-2 and HSC-4 cells (9, 12) (GB Accession number, AC005738, NM_004887). The results obtained from HSC-3 cells were rather variable, but only 3 clones out of 50 sequenced showed the site to be located upstream of +284 (one of each at +219, +253, Usually, trinucleotide for stabilization and a Kpn I or an Xho I site for cloning were added to the 5' end of the primers except as described otherwise. The amplified products were then cloned into the pGL4.10 firefly luciferase reporter vector (luc2, Promega). DNA sequences of the constructs were confirmed by DNA sequencing as described above. The insert-less pGL4.10 firefly luciferase reporter vector was used for the blank and sea pansy luciferase vector; pGL4.73 (hRluc/SV40, Promega) was used for normalization of transfection efficiency in all experiments. Vectors with a mutated sequence were produced by use of a Quick Change ® II Site-Directed Mutagenesis Kit (STRATAGENE, Cedar Creek, TX, USA); and sequences were mutated from G to A, A to G, T to C, or C to T. Sequences of the produced mutant inserts were verified by DNA sequencing. For the production of deletion mutants, primer sets for promoter constructs were prepared with the position of the newly identified transcriptional start site named as +1. The forward primers listed below were employed for PCR amplification of the gene segments, where numbers indicate those of the 5' terminal bases; underlined letters denote the Kpn I recognition sequence and bold letters indicate gene sequences. (Fig. 2) . The data were verified by repeated experiments using different clones of the reporter constructs and transfection into normal human keratinocytes (data not shown). When we surveyed the regions of the gene, we could not find any TATA-like sequence. There are many TATA-less genes (29, 31) and in these genes GC boxes often regulate the transcription of such genes (23). We could not find GC boxes in the previously proposed promoter region of the gene, either (Fig. 1) . These data also support that this region did not show any promoter activity. The construct pGL−3390/+193, containing the first (upstream) translational start site where ATG was +269) and no sites upstream of +218 were detected. In order to investigate whether the results were specific to carcinoma cells, we also determined the transcriptional start site by using normal keratinocytes. Still the upper most position was at +283, nearly the same as found when carcinoma cells were used, suggesting that the downstream transcriptional start site found here was not unique to carcinoma cells. Furthermore, the results of an in silico method for determination of human full-length cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries (7, 18) (GB Accession number; AK075514) also indicated the same position at the 5' of the cDNA of BRAK/CXCL14. Thus we concluded +284 of exon 1 of the former report (12) to be the major transcriptional start site of the gene in the squamous epithelial cells and renumbered +284 as +1 in this paper (Fig. 1) .
Determination of promoter region of the human BRAK/CXCL14 gene
The luciferase reporter gene construct encompassing Fig. 1 Base sequence of upstream and a part of exon 1 of human and mouse CXCL14. Upper case letters are the DNA sequence and some cis-elements (boxed) of the 5' region and a part of exon 1 of the human BRAK/CXCL14 gene used for determination of promoter activity. AP-1, AP-1 binding sequence; Ets1, Ets1 consensus sequence; GC, GC-box. The numbers in parentheses over the underlined bases indicate the previously proposed numbers (12) (GB Accession number, AC005738, NM_004887) and the numbers underneath them indicate the newly determined base numbers in this paper (GB Accession number AB543622). Bold underlined capital letters indicate the first (upstream) translational start site. Lower case letters are the DNA sequence and some cis-elements (boxed) of a part of the proposed exon 1 of mouse BMAC/cxcl 14 gene (GB Accession number, AC165347 and NM_019568). Vertical lines indicate identical bases between the human and mouse genes. Underlines indicate highly homologous region between the 2 species. mutated to ATT, showed significant luciferase activity (Fig. 2) . In addition, the construct containing shorter upstream sequence of the gene (pGL −557/+193 construct) also showed significant luciferase activity (Fig. 2) . These results suggest that the promoter of the BRAK/CXCL14 gene resided between −250 bp to +193 bp (between +36 to +476 of the previously proposed) of the BRAK gene in squamous epithelial cells. The pGL−557/+193 construct showed apparently 30% higher luciferase activity than the pGL−3390/+193 construct. This higher activity might have been due to the 1.6 times higher numbers of construct molecules transfected in the case of the former short insert construct, as the same weight of constructs was used for transfection in each experiment. In addition, there may have been an effect of weak suppressor elements possibly present in the upstream region (−3390 to −557) to account for the difference.
Identification of core promoter of the BRAK/CXCL14 gene
In order to find proximal core promoter elements of the gene, we produced various luciferase reporter gene constructs containing the presumptive promoter region described above. In the construct (pGL −557/+193), which contained approximately −500 base pairs upstream of the gene structure, there were two GC boxes, one AP-1 binding sequence and one tandem GC box, but there was no canonical TATA box (TATAWAWR). To confirm the core promoter elements, we constructed deletion constructs of the promoter region. As the luciferase activity of the pGL−557/+193 (previously proposed −274/+476 containing construct, see Fig. 1 ) showed significant promoter activity after transient transfection, we defined the value of this construct as 100% and used the luciferase activity of the insert-less pGL4.10 vector as a blank in subsequent experiments. No significant difference was observed among constructs containing gene fragments of −557/+193, −140/+193, and −129/+193 region (Fig. 3A) , indicating that the upstream Ets1 consensus sequence and GC-boxes 1 and 2 (see Fig. 1 ) had no transcription stimulating activity under these culture conditions. The AP-1 binding sequence deleted construct (pGL−80/+193) showed significantly (65%, P < 0.01) lower luciferase activity than the pGL−557/+193 construct (Fig. 3A) , suggesting this AP-1 binding sequence to be essential for transcriptional stimulation of the gene. A further 32 bp deletion of the promoter region, i.e., construct (pGL−48/+193) resulted in even greater significant loss (85%, P < 0.001) of the promoter activity. This region did not contain a canonical TATA box but there was an atypical TATAlike TATTAA sequence in it. Further deletion of the upstream of the gene (pGL−8/+193) showed significantly lower promoter activity (Fig. 3A) , again indicating that the TATTAA sequence was essential for transcription of the gene. All of the human CXC chemokine genes thus far reported (CXCL1 to CXCL12) contain TATA-like sequences (10) in their proximal promoter. In order to confirm the core promoter elements, we constructed mutated constructs of the AP-1 binding sequence, an atypical TATA-like (TATTAA) sequence, GC box 3 or 4 or both tandem GC box 3 and 4. The results (Fig. 3B) showed that both AP-1 and TATTAA mutants gave results similar to those obtained from the deletion mutants. That is, the AP-1 element or the TATTAA sequence mutated construct showed significantly lower (85%, P < 0.001) activity than did the wild types (Fig. 3B) , indicating that these elements were essential for the transcription of the gene. The TATTAA sequence is also present in the promoter region of 5% of genes (5) and functional analysis of some genes has shown that an Fig. 2 Promoter activity is present in the exon 1 region of the previously proposed structure of the human BRAK/ CXCL14 gene. Luciferase reporter gene constructs containing 3 kbp upstream fragment of the 5' region of the BRAK/ CXCL14 gene (pGL−3390/−249) or the fragments containing the first (upstream) translational start site (ATG was mutated to ATT) of exon 1 (pGL−3390/+193, pGL −554/+193) were produced and their luciferase activities were determined after transfection into HSC-3 cells. The promoter-less luciferase reporter gene vector (pGL4.10) was also used for transfection as a blank. Numbers indicate base numbers determined in this paper (Fig. 1) . The representative results out of 3 similar experiments are given, each run with 4 to 8 separately transfected wells, and are expressed as values relative to the activity induced by pGL −557/+193, which was set at 100%. The significance of differences between values indicated by the brackets was calculated. *P < 0.05; ***P < 0.001.
There was striking homology (95% identical bases between −108 to +1, underlined region in Fig. 1 ) observed when 5' upstream nucleotide sequences between the mouse BMAC/cxcl14 gene and human BRAK/CXCL14 gene were compared, suggesting the importance of this region for the gene expression. BRAK/CXCL14 is expressed in various kinds of cells including those of epithelial and mesenchymal origins; and the presence of an AP-1 binding sequence, TATTAA sequence, and tandem GC box or GC box 4 in the proximal promoter region might be responsible for the transcriptional regulation of this gene in those cells.
Okadaic acid stimulates expression of the BRAK gene
Okadaic acid, an inhibitor of serine/threonine phosphatases 1, 2A and 2B, affects the vast majority of cellular signaling pathways, and functions as a tumor promoter; but it also acts as an activator of tumor suppressor and induces cell apoptosis (11, 17, 32) . The opposing effects of okadaic acid might be partly responsible for the apparent contradictory reports of BRAK/CXCL14 expression on the progression of squamous cell carcinoma (9, 12, 15, 25) and adenocarcinoma (2, 3, 24, 30) . When we treated HSC-3 cells with 20 nM or 40 nM okadaic acid, the level of BRAK/CXCL14 mRNA as observed by RT-PCR was increased several fold (Fig. 4A) . This inhibitor regulates expression of various genes that are dependent on the AP-1 transcription factor (13, 28) . In order to investigate whether okadaic acid also regulates BRAK/ CXCL14 gene transcription, we tested luciferase activities after transfection of cells with various deletion and mutation constructs. Luciferase activities of pGL−557/+193 and pGL−129/+193 transfected cells were significantly stimulated (3 fold, P < 0.001 in Fig. 4B ; 3 fold, P < 0.001 in Fig. 4C ) by the addition of 40 nM okadaic acid to the culture medium, but those of pGL−80/+193 (AP-1-less) or pGL −48/+193 (AP-1 and TATTAA-less) transfected cells were not, suggesting that these AP-1 and TATTAA elements were essential for responding to the inhibitor. When the mutated AP-1 binding sequence or mutated TATTAA constructs was used for transfection, the luciferase activity was significantly lower compared with that obtained for the wild-type construct as shown in Fig. 3 B. Also the addition of okadaic acid did not stimulate the luciferase activity, even though a stimulative response was found in the case of transfection with the TATA mutant or GC box 3, 4-mutated constructs (3 fold, P < 0.001, atypical TATTAA sequence constitutes the promoter motif (6, 8, 14) . These data support that this TATTAA sequence represents an atypical TATA box also in the human BRAK/CXCL14 gene. GC box 4-and tandem GC boxes 3,4-mutated constructs but not the GC box 3-mutated one showed significantly lower activities than the wildtype promoter construct, suggesting the tandem GC box or GC box 4 was also essential for the transcription of the gene (Fig. 3B) . Fig.1 . The locations of some cis-elements are indicated, but are not to scale with the length of the DNA. Luc, luciferase reporter gene; circles, GC boxes 1 and 2, overlapped circles, tandem GC box 3 and 4; triangle, AP-1 binding element; rectangle, atypical TATA-like sequence (TATTAA). Open symbols indicate the wild-type sequence; and closed symbols, constructs containing mutated sequences as described under the MATERIALS AND METHODS. Representative results out of 3 similar experiments are given, each run with 8 separately transfected wells, and are expressed as values relative to the activity induced by pGL −557/+193, which was set at 100%. The significance of difference was calculated between pGL−557/+193 and the respective constructs. The promoter-less luciferase reporter gene vector (pGL4.10) was also used for transfection as a blank. *P < 0.05; **P < 0.01; ***P < 0.001.
ments. An atypical TATA box, the TATTAA sequence located −65 to −60 bp upstream of the transcription start site was essential for the transcriptional activity of the gene. The AP-1 binding sequence upstream of this atypical TATA box and the tandem GC box downstream of it were necessary for the transcriptional stimulation of the gene. The AP-1 binding and TATTAA sequences were essential for stimulating the luciferase activity of the constructs by okadaic acid. In addition there was Fig. 4C ), thus indicating that the AP-1 binding but not the TATTAA sequence or the tandem GC box was essential for okadaic acid-stimulated BRAK/ CXCL14 gene expression in the cells.
In conclusion, we found the major transcriptional start site was at +284 in the previously proposed exon-1 region of the BRAK/CXCL14 gene in human squamous epithelial cells. By functional analysis of the upstream of the transcriptional start site, we showed the presence of 3 core promoter ele- Fig. 1 . The locations of some cis-elements are indicated, but are not to scale with the length of DNA. Abbreviations and symbols are the same as in Fig. 3 . The significance of difference was calculated between cultures in the absence and presence of 40 nM okadaic acid. The significance of difference between respective constructs in the absence of okadaic acid was essentially the same as in Fig. 3 , and was thus omitted for clarity. **P < 0.01; ***P < 0.001. striking homology (95% base identity) in the 5' upstream region of the human and mouse genes supporting the importance of this region for the expression of the gene. Our present results offer a new tool to clarify the precise transcriptional regulatory mechanisms of the gene for human BRAK/CXCL14, a tumor-suppressing chemokine.
